Drugs / Conjugated equine estrogens
Conjugated equine estrogens
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02274571 | Sep 2015 → Apr 2017 | — | Pennington Biomedical Research Center | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00234676 | Oct 2003 → Mar 2006 | Parkinson disease | The Parkinson Study Group | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00000430 | Oct 1999 → Sep 2004 | osteoporosis | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Terminated | No outcome recorded |
| Phase 3 | NCT00000611 | ? → Mar 2005 | breast neoplasm, colonic neoplasm, coronary artery disorder, disease of bone structure +2 | National Heart, Lung, and Blood Institute (NHLBI) | Completed | Mixed |
| Phase 41 trial · 1 missed | ||||||
| Phase 4 | NCT00392093 | Nov 1997 → Dec 2001 | systemic lupus erythematosus | National Institute of Medical Sciences and Nutrition Salvador Zubiran | Completed | Missed primary |
| Comparator or background therapy4 trials | ||||||
| Phase 2 | NCT00302731 Comparator | Feb 2006 → Jan 2014 | premature menopause | Jeanne Drisko, MD, CNS, FACN | Terminated | No outcome recorded |
| Phase 3 | NCT01070979 Comparator | Feb → Sep 2003 | — | Warner Chilcott | Completed | No outcome recorded |
| Phase 4 | NCT00154180 Comparator | Sep 2005 → May 2012 | arteriosclerosis disorder | Kronos Longevity Research Institute | Unknown | No outcome recorded |
| — | NCT02524561 Comparator | Sep 2005 → Dec 2013 | breast disorder | Brigham and Women's Hospital | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Conjugated equine estrogens | “The Women's Health Initiative Estrogen-Aone trial comparing conjugated equine estrogens (CEE) with placebo was stopped early because of an increased stroke incidence and no...” PMID 16609086 ↗ Apr 20068“receive conjugated equine estrogens 0.45 mg combined with medroxyprogesteroneacetate 1.5 mg placed in a placebo capsule to disguise contents from participant and study team” NCT00302731 ↗ “Duavee™, combination of CE(conjugated equine estrogens) and BZA (bazedoxifene)” NCT02274571 ↗ “Estrogen Replacement Therapy (Conjugated Equine Estrogens 0.625 mg Daily)” NCT00234676 ↗ “Conjugated equine estrogens 0.45 mg/day” NCT02524561 ↗ |
| Known as | CEE | “The Women's Health Initiative Estrogen-Aone trial comparing conjugated equine estrogens (CEE) with placebo was stopped early because of an increased stroke incidence and no...” PMID 16609086 ↗ Apr 2006 |
| Known as | conjugated equine oestrogen | “Women aged 50-79 years who had undergone hysterectomy and had expected 3-year survival and mammography clearance were randomly allocated by a computerised, permuted block...” PMID 22401913 ↗ Mar 2012 |
| Known as | o-CEE | “0.45 mg/d oral conjugated equine estrogens (o-CEE)” PMID 32015261 ↗ Mar 2020 |
| Known as | Premarin | “1. Conjugated equine estrogens 0.625 mg/day plus 5 mg/day of medroxyprogesterone acetate p.o. for the first 10 days per-month (Premarin and Cycrin, respectively, Laboratorios Wyeth).” NCT00392093 ↗ |
| Route | Oral | “to receive oral conjugated equine oestrogen” PMID 22401913 ↗ Mar 2012 |